Given that chronic microglial activation is a central feature of many neurodegenerative diseases, our results provide strong evidence for the potential of BET inhibitors as a novel therapeutic approach for treating conditions characterized by neuroinflammation. This evidence concerns the gene DNER and neurodegenerative disease.